达比加群酯对于非瓣膜性房颤患者抗凝的有效性和安全性分析

The observation of efficacy and safety of dabigatran in treatment for anticoagulation in patients with non-valvular atrial fibrillation

目的 对非瓣膜性房颤患者应用新型口服抗凝药物达比加群酯预防卒中和栓塞,观察达比加群酯的有效性和安全性.方法 回顾性分析2012年4月～2013年12月收入我院心内科的非瓣膜性房颤患者259例,其中观察组125例和对照组134例,观察组予达比加群酯抗凝,对照组予华法林抗凝.观察脑卒中、栓塞或血栓形成、心血管事件死亡以及出血的发生率.结果 观察组患者脑卒中（14.4％）、栓塞或血栓形成（8.8％）、心血管事件死亡（2.4％）、出血（5.6％）均显著低于对照组,差异有统计学意义（P＜0.05）.结论 达比加群酯在预防脑卒中和血栓形成以及降低出血风险方面均优于调整剂量的华法林,具有较好的有效性和安全性.

Objective To observe efficacy and safety in patients with non-valvular atrial fibrillation on the application of dabigatran. Methods 259 cases of patients with non-valvular atrial fibrillation from April 2012 to December 2013 were retrospectively analyzed,included observation group （n=125） and control group （n=134）, observation group were given treatment of dabigatran, control group were given warfarin.The incidence of stroke, thrombosis, death and bleeding were observed. Results The incidence of cerebral stroke （14.4%）,thrombosis （8.8%）, death due to cardiovascular events （2.4%） and bleeding （5.6%） in observation group were significantly lower than the control group. Conclusion Dabigatran can effectively decrease the incidence of stroke and bleeding in patients with non-valvular atrial fibrilla- tion, has better efficacy and safety than warfarin.